Merck & Co., Inc. is a global health care company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products. The company’s operations are managed on a products basis and include segments that reflect its strategic resource allocation and investment decisions. The performance during 2018 demonstrates execution of its innovation strategy, with revenue growth driven by focused investment in the research and development pipeline, disciplined allocation of resources, and operational flexibility. Merck's strategy includes augmenting its portfolio and pipeline with external innovation, which is crucial for maintaining competitive advantage in a rapidly evolving market. The company has entered into strategic collaborations, such as with Eisai Co., Ltd. for the co-development and co-commercialization of lenvima, and has acquired companies like Viralytics Limited, enhancing its capabilities in immunotherapy. Merck’s commitment to advancing its leadership in oncology is evident through its focused commercial execution and the achievement of important regulatory milestones. The company also faced challenges, such as competitive pressures and the impact of a cyber-attack that disrupted operations and affected sales. The cyber-attack resulted in significant costs related to remediation efforts and manufacturing variances, highlighting the importance of IT governance and operational efficiency in managing risks. Merck’s strategic management practices include continuous evaluation of its research and development resources, with a focus on maximizing the value of its approved medicines and vaccines through new indications and formulations. The company’s investment choices reflect its commitment to enhancing its technology portfolio and capabilities, which are essential for meeting evolving consumer demands and maintaining market agility. Merck’s financial activities, including capital expenditures aimed at increasing future manufacturing capacity, are aligned with its long-term growth objectives. The company’s ability to mobilize and deploy IT-based resources in conjunction with leveraging other organizational capabilities is fundamental to transforming its business processes and achieving performance gains. Merck’s operational strategies are designed to optimize its internal processes and enhance its overall organizational effectiveness, ensuring that it remains responsive to market dynamics and competitive forces. The firm’s focus on information management capability underscores the importance of providing accurate, timely, and reliable data to support decision-making and strategic resource allocation. As the company navigates regulatory contexts and environmental factors, it remains committed to leveraging its IT capabilities to drive business transformation and improve firm performance.